Skip to content
20-F

Annual Report (Foreign)

4D pharma plc

0001493152-22-008593

← back to feed
Filed
Mar 31, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Dec 31, 2021 180.3M sh
Capex FY 2021 · Dec 31, 2021 $279K
Operating Cash Flow FY 2021 · Dec 31, 2021 −$37.92M
Long Term Debt FY 2021 · Dec 31, 2021 $11.84M
Cash And Equivalents FY 2021 · Dec 31, 2021 $20.97M
Stockholders Equity FY 2021 · Dec 31, 2021 $32.42M
Current Liabilities FY 2021 · Dec 31, 2021 $6.62M
Total Liabilities FY 2021 · Dec 31, 2021 $26.38M
Current Assets FY 2021 · Dec 31, 2021 $34.5M
Total Assets FY 2021 · Dec 31, 2021 $58.79M
Sga Expense FY 2021 · Dec 31, 2021 $15.89M
Rd Expense FY 2021 · Dec 31, 2021 $21.63M
Net Income FY 2021 · Dec 31, 2021 −$31.94M
Operating Income FY 2021 · Dec 31, 2021 −$37.26M
Revenue FY 2021 · Dec 31, 2021 $718K